Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Normal breast-derived epithelial cells with luminal and intrinsic subtype-enriched gene expression document inter-individual differences in their differentiation cascade.

Kumar B, Prasad MS, Bhat-Nakshatri P, Anjanappa M, Kalra M, Marino N, Storniolo AMV, Rao X, Liu S, Wan J, Liu Y, Nakshatri H.

Cancer Res. 2018 Jul 11. pii: canres.0509.2018. doi: 10.1158/0008-5472.CAN-18-0509. [Epub ahead of print]

PMID:
29997232
2.

Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.

Padua MB, Bhat-Nakshatri P, Anjanappa M, Prasad MS, Hao Y, Rao X, Liu S, Wan J, Liu Y, McElyea K, Jacobsen M, Sandusky G, Althouse S, Perkins S, Nakshatri H.

Breast Cancer Res. 2018 May 2;20(1):35. doi: 10.1186/s13058-018-0963-5.

3.

A Spectrum Graph-Based Protein Sequence Filtering Algorithm for Proteoform Identification by Top-Down Mass Spectrometry.

Yang R, Zhu D, Kou Q, Bhat-Nakshatri P, Nakshatri H, Wu S, Liu X.

Proceedings (IEEE Int Conf Bioinformatics Biomed). 2017 Nov;2017:222-229. doi: 10.1109/BIBM.2017.8217653. Epub 2017 Dec 18.

PMID:
29503761
4.

Mutational landscape of RNA-binding proteins in human cancers.

Neelamraju Y, Gonzalez-Perez A, Bhat-Nakshatri P, Nakshatri H, Janga SC.

RNA Biol. 2018 Jan 2;15(1):115-129. doi: 10.1080/15476286.2017.1391436. Epub 2017 Nov 14.

5.

Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer.

Wang R, Bhat-Nakshatri P, Padua MB, Prasad MS, Anjanappa M, Jacobson M, Finnearty C, Sefcsik V, McElyea K, Redmond R, Sandusky G, Penthala N, Crooks PA, Liu J, Zimmers T, Nakshatri H.

Mol Cancer Ther. 2017 Dec;16(12):2747-2758. doi: 10.1158/1535-7163.MCT-17-0717. Epub 2017 Oct 4.

6.

A system for detecting high impact-low frequency mutations in primary tumors and metastases.

Anjanappa M, Hao Y, Simpson ER, Bhat-Nakshatri P, Nelson JB, Tersey SA, Mirmira RG, Cohen-Gadol AA, Saadatzadeh MR, Li L, Fang F, Nephew KP, Miller KD, Liu Y, Nakshatri H.

Oncogene. 2018 Jan 11;37(2):185-196. doi: 10.1038/onc.2017.322. Epub 2017 Sep 11.

7.

Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.

Bhat-Nakshatri P, Goswami CP, Badve S, Magnani L, Lupien M, Nakshatri H.

Cancer Res. 2016 Jul 1;76(13):3989-4001. doi: 10.1158/0008-5472.CAN-15-3174. Epub 2016 Apr 25.

8.

Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization.

Nakshatri H, Anjanappa M, Bhat-Nakshatri P.

Sci Rep. 2015 Aug 27;5:13526. doi: 10.1038/srep13526.

9.

Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells.

Burnett RM, Craven KE, Krishnamurthy P, Goswami CP, Badve S, Crooks P, Mathews WP, Bhat-Nakshatri P, Nakshatri H.

Oncotarget. 2015 May 20;6(14):12682-96.

10.

NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.

Nakshatri H, Appaiah HN, Anjanappa M, Gilley D, Tanaka H, Badve S, Crooks PA, Mathews W, Sweeney C, Bhat-Nakshatri P.

Cell Death Dis. 2015 Jan 22;6:e1608. doi: 10.1038/cddis.2014.569.

11.

Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle.

Chen D, Goswami CP, Burnett RM, Anjanappa M, Bhat-Nakshatri P, Muller W, Nakshatri H.

Cancer Res. 2014 Aug 15;74(16):4270-81. doi: 10.1158/0008-5472.CAN-13-2817. Epub 2014 Jun 30.

12.

Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.

Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW Jr, Nakshatri H.

Sci Rep. 2013;3:2530. doi: 10.1038/srep02530.

13.

ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer.

Chen D, Bhat-Nakshatri P, Goswami C, Badve S, Nakshatri H.

Cancer Res. 2013 Sep 15;73(18):5821-33. doi: 10.1158/0008-5472.CAN-13-1080. Epub 2013 Jul 5.

14.

Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing.

Bhat-Nakshatri P, Song EK, Collins NR, Uversky VN, Dunker AK, O'Malley BW, Geistlinger TR, Carroll JS, Brown M, Nakshatri H.

BMC Med Genomics. 2013 Jun 11;6:21. doi: 10.1186/1755-8794-6-21.

15.

Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.

Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P, Liu Y, Nakshatri H.

Oncogene. 2011 Mar 17;30(11):1290-301. doi: 10.1038/onc.2010.510. Epub 2010 Nov 8.

PMID:
21057539
16.

SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.

Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H.

BMC Cancer. 2010 Aug 6;10:411. doi: 10.1186/1471-2407-10-411.

17.

ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.

Appaiah H, Bhat-Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H.

Cancer Biol Ther. 2010 Sep 15;10(6):600-14. Epub 2010 Sep 4.

18.

Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.

Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H.

Am J Pathol. 2010 May;176(5):2139-49. doi: 10.2353/ajpath.2010.090477. Epub 2010 Mar 12.

19.

Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.

McCune K, Bhat-Nakshatri P, Thorat MA, Nephew KP, Badve S, Nakshatri H.

Cancer Res. 2010 Jan 15;70(2):685-96. doi: 10.1158/0008-5472.CAN-09-1530. Epub 2010 Jan 12.

20.

Estradiol-regulated microRNAs control estradiol response in breast cancer cells.

Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H.

Nucleic Acids Res. 2009 Aug;37(14):4850-61. doi: 10.1093/nar/gkp500. Epub 2009 Jun 14.

21.

NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.

Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA.

Cancer Lett. 2009 Jun 18;278(2):145-155. doi: 10.1016/j.canlet.2008.12.031. Epub 2009 Mar 20.

PMID:
19303700
22.

AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.

Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, Brown M, Badve S, Liu Y, Nakshatri H.

Mol Cell Biol. 2008 Dec;28(24):7487-503. doi: 10.1128/MCB.00799-08. Epub 2008 Oct 6.

23.

Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.

Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ Jr, Broxmeyer HE, Kopelovich L, Nakshatri H.

Oncogene. 2007 May 17;26(23):3329-37. Epub 2006 Nov 27.

PMID:
17130833
24.

CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.

Breast Cancer Res. 2006;8(5):R59.

25.

Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ.

Prostate. 2006 Oct 1;66(14):1498-511.

PMID:
16921510
26.

Negative regulation of MHC class II gene expression by CXCR4.

Sheridan C, Sadaria M, Bhat-Nakshatri P, Goulet R Jr, Edenberg HJ, McCarthy BP, Chang CH, Srour EF, Nakshatri H.

Exp Hematol. 2006 Aug;34(8):1085-92.

PMID:
16863915
27.

NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2.

Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H.

Oncogene. 2007 Feb 1;26(5):711-24. Epub 2006 Jul 24.

PMID:
16862183
28.

The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12.

Kishimoto H, Wang Z, Bhat-Nakshatri P, Chang D, Clarke R, Nakshatri H.

Carcinogenesis. 2005 Oct;26(10):1706-15. Epub 2005 May 25.

PMID:
15917309
29.

The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells.

Wollmann W, Goodman ML, Bhat-Nakshatri P, Kishimoto H, Goulet RJ Jr, Mehrotra S, Morimiya A, Badve S, Nakshatri H.

Carcinogenesis. 2005 May;26(5):900-7. Epub 2005 Jan 27.

PMID:
15677629
30.

TNFalpha resistance in MCF-7 breast cancer cells is associated with altered subcellular localization of p21CIP1 and p27KIP1.

Wang Z, Kishimoto H, Bhat-Nakshatri P, Crean C, Nakshatri H.

Cell Death Differ. 2005 Jan;12(1):98-100. No abstract available.

31.

Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate.

Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L.

Clin Cancer Res. 2004 Aug 15;10(16):5501-7.

33.

Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function.

Bhat-Nakshatri P, Campbell RA, Patel NM, Newton TR, King AJ, Marshall MS, Ali S, Nakshatri H.

Br J Cancer. 2004 Feb 23;90(4):853-9.

34.

NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4.

Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H.

J Biol Chem. 2003 Jun 13;278(24):21631-8. Epub 2003 Apr 9.

35.
36.

Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H.

J Biol Chem. 2001 Mar 30;276(13):9817-24. Epub 2001 Jan 3.

37.

Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide.

Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, Rice S, Gelfanov V, Boswell SH, Goulet RJ Jr, Sledge GW Jr, Nakshatri H.

Oncogene. 2000 Aug 24;19(36):4159-69.

38.

The orphan receptor COUP-TFII regulates G2/M progression of breast cancer cells by modulating the expression/activity of p21(WAF1/CIP1), cyclin D1, and cdk2.

Nakshatri H, Mendonca MS, Bhat-Nakshatri P, Patel NM, Goulet RJ Jr, Cornetta K.

Biochem Biophys Res Commun. 2000 Apr 21;270(3):1144-53.

PMID:
10772965
39.

Negative regulation of transactivation function but not DNA binding of NF-kappaB and AP-1 by IkappaBbeta1 in breast cancer cells.

Newton TR, Patel NM, Bhat-Nakshatri P, Stauss CR, Goulet RJ Jr, Nakshatri H.

J Biol Chem. 1999 Jun 25;274(26):18827-35.

40.

NF-kappaB activation and interleukin 6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin 1alpha.

Bhat-Nakshatri P, Newton TR, Goulet R Jr, Nakshatri H.

Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6971-6.

42.

Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth.

Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr.

Mol Cell Biol. 1997 Jul;17(7):3629-39.

43.

Differential effect of Nonidet P40 on DNA binding of transcription factors.

Nakshatri H, Bhat-Nakshatri P.

Anal Biochem. 1997 Jun 15;249(1):103-4. No abstract available.

PMID:
9193715
44.
45.

Isolation of retinoic acid-repressed genes from P19 embryonal carcinoma cells.

Nakshatri H, Bouillet P, Bhat-Nakshatri P, Chambon P.

Gene. 1996 Sep 26;174(1):79-84.

PMID:
8863732

Supplemental Content

Loading ...
Support Center